[Ip-health] Congressional Briefing: Improving Antimalarial Drug Quality in Africa

[James Love]

Philip Hedger says its fine to share this with ip-health. Jamie

-------- Forwarded Message --------
From: Hedger, Philip <Philip.Hedger@pfizer.com>
To: james.love@keionline.org
Subject: Re: [Ip-health] Congressional Briefing: Improving
AntimalarialDrug Quality in Africa
Date: Fri, 6 Jun 2008 07:52:25 -0400

Jamie
Could it be because they, as we, share a desire to improve the management o=
f Malaria? And one of the very soluable ways of doing so is eradicating har=
mful or useless substances - for which patients often pay good money they c=
an ill afford from their own pockets.
Why else do you think Tren and Bate are committed to this cause?
Take care
Philip
--------------------------
Sent from my BlackBerry Wireless Handheld


-----Original Message-----
From: ip-health-admin@lists.essential.org
To: Philip Coticelli
CC: IPHealth
Sent: Thu Jun 05 18:36:08 2008
Subject: Re: [Ip-health] Congressional Briefing: Improving AntimalarialDrug=
 Quality in Africa

Why would the Congressional Malaria caucus give airtime to industry
shills like Roger Bate and Richard Tren?

  jamie

On Wed, 2008-06-04 at 12:50 -0400, Philip Coticelli wrote:
> --
> [ Picked text/plain from multipart/alternative ]
>   Africa Fighting Malaria in conjunction with the Congressional Malaria
> Caucus
> invites you to attend the Congressional briefing
> **
> *Improving Antimalarial Drug Quality in Africa*
> **
> Tuesday, June 10, 2008
> 10:00-11:30 am
> The Rayburn House Office Building
> Room 2200
> Washington DC
>
> A recent study published in PLoS ONE found approximately one third of
> antimalarial drugs sold in private pharmacies in six African countries we=
re
> substandard or fake.  Numerous artemisinin monotherapy tablets were found=
 on
> sale, despite being proscribed by the World Health Organization in 2006.
> Improving the quality of malaria treatment in Africa, where the majority =
of
> people access their medicines from the private sector, is vital.  Resista=
nce
> to artemisinin therapies has already been found in South East Asia.  With=
 no
> new class of drugs likely to replace artemisinin-based combination therap=
ies
> for at least a decade, great care must be taken to control for the